Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Protein Kinase Inhibitors"" wg kryterium: Temat


Tytuł :
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Autorzy :
Liu W; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Liu X; School of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Tian L; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Gao Y; School of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Liu W; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Chen H; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Jiang X; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Xu Z; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
Ding H; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China. Electronic address: .
Zhao Q; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113554. Date of Electronic Publication: 2021 May 29.
Typ publikacji :
Journal Article
MeSH Terms :
Alzheimer Disease/*drug therapy
Glycogen Synthase Kinase 3 beta/*antagonists & inhibitors
Harmine/*pharmacology
Neuroprotective Agents/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Protein-Serine-Threonine Kinases/*antagonists & inhibitors
Protein-Tyrosine Kinases/*antagonists & inhibitors
Alzheimer Disease/metabolism ; Cell Line ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Design ; Glycogen Synthase Kinase 3 beta/metabolism ; Harmine/chemical synthesis ; Harmine/chemistry ; Humans ; Models, Molecular ; Molecular Structure ; Neuroprotective Agents/chemical synthesis ; Neuroprotective Agents/chemistry ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Protein-Serine-Threonine Kinases/metabolism ; Protein-Tyrosine Kinases/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.
Autorzy :
Sagar S; Eppley Institute for Cancer Research, Omaha, NE, USA.
Singh S; Eppley Institute for Cancer Research, Omaha, NE, USA.
Mallareddy JR; Eppley Institute for Cancer Research, Omaha, NE, USA.
Sonawane YA; Eppley Institute for Cancer Research, Omaha, NE, USA.
Napoleon JV; Eppley Institute for Cancer Research, Omaha, NE, USA.
Rana S; Eppley Institute for Cancer Research, Omaha, NE, USA.
Contreras JI; Eppley Institute for Cancer Research, Omaha, NE, USA.
Rajesh C; Eppley Institute for Cancer Research, Omaha, NE, USA.
Ezell EL; Eppley Institute for Cancer Research, Omaha, NE, USA.
Kizhake S; Eppley Institute for Cancer Research, Omaha, NE, USA.
Garrison JC; Department of Pharmaceutical Sciences, Omaha, NE, USA.
Radhakrishnan P; Eppley Institute for Cancer Research, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, Omaha, NE, USA; Department of Genetics Cell Biology and Anatomy, Omaha, NE, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: .
Natarajan A; Eppley Institute for Cancer Research, Omaha, NE, USA; Department of Pharmaceutical Sciences, Omaha, NE, USA; Department of Genetics Cell Biology and Anatomy, Omaha, NE, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113579. Date of Electronic Publication: 2021 May 30.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
I-kappa B Kinase/*antagonists & inhibitors
Pancreatic Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Quinoxalines/*pharmacology
Urea/*pharmacology
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; I-kappa B Kinase/metabolism ; Mice ; Molecular Structure ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Phosphorylation/drug effects ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinoxalines/chemical synthesis ; Quinoxalines/chemistry ; Structure-Activity Relationship ; Urea/analogs & derivatives ; Urea/chemistry
Czasopismo naukowe
Tytuł :
A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
Autorzy :
Mustafa M; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt.
Abd El-Hafeez AA; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. Electronic address: .
Abdelhamid D; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Katkar GD; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Mostafa YA; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, 71526, Egypt.
Ghosh P; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA; Department of Medicine, University of California San Diego, La Jolla, CA, USA; Moores Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA; Veterans Affairs Medical Center, La Jolla, CA, USA.
Hayallah AM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, 71526, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Sphinx University, New Assiut, Egypt.
Abuo-Rahma GEA; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113569. Date of Electronic Publication: 2021 May 29.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Focal Adhesion Kinase 1/*antagonists & inhibitors
Histone Deacetylase 2/*antagonists & inhibitors
Histone Deacetylase Inhibitors/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Triazoles/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Apoptosis/drug effects ; Benzamides/chemistry ; Benzamides/pharmacology ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Focal Adhesion Kinase 1/metabolism ; Histone Deacetylase 2/metabolism ; Histone Deacetylase Inhibitors/chemical synthesis ; Histone Deacetylase Inhibitors/chemistry ; Humans ; Hydroxamic Acids/chemistry ; Hydroxamic Acids/pharmacology ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Structure-Activity Relationship ; Triazoles/chemistry ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Autorzy :
Wang S; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhang RH; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Zhang H; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Wang YC; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Yang D; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhao YL; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Yan GY; Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Henan University, Zhengzhou, PR China.
Xu GB; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Guan HY; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhou YH; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Cui DB; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Liu T; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Li YJ; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Liao SG; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China. Electronic address: .
Zhou M; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113573. Date of Electronic Publication: 2021 May 29.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Angiogenesis Inhibitors/*pharmacology
Antineoplastic Agents/*pharmacology
Focal Adhesion Kinase 1/*antagonists & inhibitors
Neovascularization, Pathologic/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Angiogenesis Inhibitors/chemical synthesis ; Angiogenesis Inhibitors/chemistry ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cells, Cultured ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Focal Adhesion Kinase 1/metabolism ; Humans ; Molecular Structure ; Neovascularization, Pathologic/metabolism ; Neovascularization, Pathologic/pathology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Cyclic mimetics of kinase-inhibitory region of Suppressors of Cytokine Signaling 1: Progress toward novel anti-inflammatory therapeutics.
Autorzy :
La Manna S; Department of Pharmacy - University of Naples 'Federico II', 80134, Naples, Italy; Renal and Vascular Inflammation Group, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Autonoma University of Madrid (UAM), 28040, Madrid, Spain.
Lopez-Sanz L; Renal and Vascular Inflammation Group, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Autonoma University of Madrid (UAM), 28040, Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28040, Madrid, Spain.
Bernal S; Renal and Vascular Inflammation Group, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Autonoma University of Madrid (UAM), 28040, Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28040, Madrid, Spain.
Fortuna S; Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127, Trieste, Italy.
Mercurio FA; Institute of Biostructures and Bioimaging - CNR, 80134, Naples, Italy.
Leone M; Institute of Biostructures and Bioimaging - CNR, 80134, Naples, Italy.
Gomez-Guerrero C; Renal and Vascular Inflammation Group, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Autonoma University of Madrid (UAM), 28040, Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28040, Madrid, Spain.
Marasco D; Department of Pharmacy - University of Naples 'Federico II', 80134, Naples, Italy. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 05; Vol. 221, pp. 113547. Date of Electronic Publication: 2021 May 14.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Inflammatory Agents/*pharmacology
Peptidomimetics/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Suppressor of Cytokine Signaling 1 Protein/*antagonists & inhibitors
Animals ; Anti-Inflammatory Agents/chemical synthesis ; Anti-Inflammatory Agents/chemistry ; Cells, Cultured ; Dose-Response Relationship, Drug ; Mice ; Molecular Structure ; Peptidomimetics/chemical synthesis ; Peptidomimetics/chemistry ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Structure-Activity Relationship ; Suppressor of Cytokine Signaling 1 Protein/metabolism
Czasopismo naukowe
Tytuł :
Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
Autorzy :
Jiang B; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Jiang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Kaltheuner IH; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Iniguez AB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; The Broad Institute, Cambridge, MA, 02142, USA.
Anand K; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Ferguson FM; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Seong BKA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; The Broad Institute, Cambridge, MA, 02142, USA.
Greifenberg AK; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Dust S; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Kwiatkowski NP; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; The Broad Institute, Cambridge, MA, 02142, USA.
Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Geyer M; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 05; Vol. 221, pp. 113481. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Discovery*
Anilides/*pharmacology
CDC2 Protein Kinase/*antagonists & inhibitors
Cyclin-Dependent Kinases/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Anilides/chemical synthesis ; Anilides/chemistry ; Animals ; CDC2 Protein Kinase/metabolism ; Cells, Cultured ; Cyclin-Dependent Kinases/metabolism ; Dose-Response Relationship, Drug ; Humans ; Male ; Mice ; Microsomes, Liver/chemistry ; Microsomes, Liver/metabolism ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.
Autorzy :
Ayati A; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Moghimi S; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Toolabi M; Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: .
Foroumadi A; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 05; Vol. 221, pp. 113523. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*pharmacology
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Humans ; Molecular Structure ; Neoplasms/metabolism ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry
Czasopismo naukowe
Tytuł :
Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer.
Autorzy :
Nagashio K; Department of Cardiology, Faculty of Medicine, University of Tsukuba.
Tajiri K; Department of Cardiology, Faculty of Medicine, University of Tsukuba.
Sato K; Department of Cardiology, Faculty of Medicine, University of Tsukuba.
Ieda M; Department of Cardiology, Faculty of Medicine, University of Tsukuba.
Pokaż więcej
Źródło :
International heart journal [Int Heart J] 2021 Sep 30; Vol. 62 (5), pp. 1171-1175. Date of Electronic Publication: 2021 Sep 07.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Cardiomyopathies/*chemically induced
Erlotinib Hydrochloride/*toxicity
Protein Kinase Inhibitors/*toxicity
Aged ; Biopsy/methods ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/secondary ; Cardiomyopathies/pathology ; Cardiotoxicity/complications ; Disease Progression ; Dyspnea/diagnosis ; Dyspnea/etiology ; Erlotinib Hydrochloride/adverse effects ; Erlotinib Hydrochloride/therapeutic use ; Female ; Follow-Up Studies ; Heart Failure/diagnosis ; Heart Failure/drug therapy ; Heart Failure/etiology ; Humans ; Lung Neoplasms/pathology ; Neoplasm Metastasis/pathology ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Autorzy :
Reich DS; Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. Electronic address: .
Arnold DL; NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, QC, Canada.
Vermersch P; Lille Neuroscience et Cognition, University Lille, INSERM UMR-S1172, CHU Lille, FHU Imminent, Lille, France.
Bar-Or A; Center for Neuroinflammation and Neurotherapeutics and the Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Fox RJ; MellenCenter for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
Matta A; Sanofi, Cambridge, MA, USA.
Turner T; Sanofi, Cambridge, MA, USA.
Wallström E; Sanofi, Cambridge, MA, USA.
Zhang X; Sanofi, Cambridge, MA, USA.
Mareš M; Department of Neurology, Pardubice Regional Hospital, Pardubice, Czech Republic.
Khabirov FA; Republican Clinical Neurological Center, Kazan, Russia.
Traboulsee A; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Pokaż więcej
Corporate Authors :
Tolebrutinib Phase 2b Study Group
Źródło :
The Lancet. Neurology [Lancet Neurol] 2021 Sep; Vol. 20 (9), pp. 729-738.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Outcome Assessment, Health Care*
Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors
Central Nervous System/*drug effects
Inflammation/*drug therapy
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Adult ; Central Nervous System/diagnostic imaging ; Central Nervous System/immunology ; Central Nervous System/pathology ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; Inflammation/diagnostic imaging ; Inflammation/immunology ; Inflammation/pathology ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting/immunology ; Multiple Sclerosis, Relapsing-Remitting/pathology ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Recurrence ; Young Adult
Czasopismo naukowe
Tytuł :
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
Autorzy :
Adnan-Awad S; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
Kankainen M; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Mustjoki S; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Sep; Vol. 62 (9), pp. 2064-2078. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Drug Resistance, Neoplasm ; Fusion Proteins, bcr-abl/genetics ; Humans ; Mutation ; Oncogenes
Czasopismo naukowe
Tytuł :
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Autorzy :
Cho HJ; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Baek DW; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Kim J; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Lee JM; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Moon JH; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Sohn SK; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Pokaż więcej
Źródło :
Expert review of hematology [Expert Rev Hematol] 2021 Sep; Vol. 14 (9), pp. 819-830. Date of Electronic Publication: 2021 Aug 22.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Adenine/*analogs & derivatives
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Piperidines/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Adenine/adverse effects ; Adenine/pharmacology ; Adenine/therapeutic use ; Aged ; COVID-19/complications ; Disease Management ; Drug Interactions ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/therapy ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Male ; Piperidines/adverse effects ; Piperidines/pharmacology ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Tytuł :
Sustained Tumor Control With MAPK Inhibition in BRAF V600-Mutant Adult Glial and Glioneuronal Tumors.
Autorzy :
Berzero G; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Bellu L; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Baldini C; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Ducray F; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Guyon D; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Eoli M; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Silvani A; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Dehais C; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Idbaih A; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Younan N; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Nguyen-Them L; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Gaillard S; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Pasqualetti F; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Lepage-Seydoux C; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Sekkate S; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Tresca P; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Kas A; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Gratieux J; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Ammari S; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Saragoussi E; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Savatovsky J; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Delattre JY; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Hoang-Xuan K; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Meyronet D; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Villa C; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Bielle F; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Sanson M; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Touat M; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris.
Di Stefano AL; From Sorbonne Université (G.B., L.B., C.D., A.I., J.-Y.D., K.H.-X., F.B., M.S., M.T., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Radiation Therapy Unit (L.B.), Imaging and Medical Physics Department, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; Drug Development Department (C.B.), Institut Gustave Roussy and Université Paris-Saclay, Villejuif; Department of Neuroncology (F.D.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Department of Neurology (D.G., N.Y., A.L.D.S.), Department of Neurosurgery (S.G.), Service de Pharmacie (C.L.-S.), Department of Oncology (S.S.), Department of Neuroradiology (J.G.), and Department of Pathology (C.V.), Hôpital Foch, Suresnes, France; Neuro-oncology Unit (M.E., A.S.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Service de Neurologie (L.N.T.), Centre Hospitalier Perpignan, France; Radiation Oncology (F.P.), Department of Medicine and Oncology, University Hospital, Pisa, Italy; Clinical Research Unit (P.T.), Institut Curie, Paris; Department of Nuclear Medicine (A.K.), AP-HP GH Pitié-Salpêtrière, Paris; Department of Diagnostic Radiology (S.A.), Institut Gustave Roussy, Villejuif, France; Neuroradiology Unit (E.S., J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Department of Pathology (D.M.), Eastern Hospital Group, Lyon Civil Hospices; Department of Neuropathology (F.B.), AP-HP, Hôpital de la Pitié-Salpêtrière; and Onconeurotek Tumor Bank (F.B., M.S.), Institut du Cerveau et de la Moelle Épinière (ICM), Paris, France. Dr. Berzero is currently at Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Dr. Gaillard is currently at the Department of Neurosurgery, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris. .
Pokaż więcej
Źródło :
Neurology [Neurology] 2021 Aug 17; Vol. 97 (7), pp. e673-e683. Date of Electronic Publication: 2021 Jun 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Outcome Assessment, Health Care*
Brain Neoplasms/*drug therapy
Glioma/*drug therapy
Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins B-raf/*genetics
Adult ; Astrocytoma/drug therapy ; Astrocytoma/genetics ; Azetidines/pharmacology ; Brain Neoplasms/genetics ; Databases, Factual ; Female ; Ganglioglioma/drug therapy ; Ganglioglioma/genetics ; Glioma/genetics ; Humans ; Imidazoles/pharmacology ; Karnofsky Performance Status ; MAP Kinase Kinase Kinases/antagonists & inhibitors ; Male ; Middle Aged ; Oximes/pharmacology ; Piperidines/pharmacology ; Progression-Free Survival ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Pyridones/pharmacology ; Pyrimidinones/pharmacology ; Retrospective Studies ; Vemurafenib/pharmacology ; raf Kinases/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma.
Autorzy :
Uehling DE; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Joseph B; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Chung KC; Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada.
Zhang AX; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Ler S; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Prakesch MA; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Poda G; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.
Grouleff J; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Aman A; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.
Kiyota T; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Leung-Hagesteijn C; Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada.
Konda JD; Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada.
Marcellus R; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Griffin C; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Subramaniam R; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Abibi A; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Strathdee CA; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Isaac MB; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
Al-Awar R; Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
Tiedemann RE; Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Aug 12; Vol. 64 (15), pp. 11129-11147. Date of Electronic Publication: 2021 Jul 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Design*
Antineoplastic Agents/*pharmacology
G-Protein-Coupled Receptor Kinases/*antagonists & inhibitors
Multiple Myeloma/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; G-Protein-Coupled Receptor Kinases/metabolism ; Humans ; Mice ; Models, Molecular ; Molecular Structure ; Multiple Myeloma/metabolism ; Multiple Myeloma/pathology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemical synthesis ; Quinazolines/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.
Autorzy :
Fu L; Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China.
Zhang J; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Shen B; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Kong L; Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China.
Liu Y; Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China.
Tu W; Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China.
Wang W; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Cai X; Department of Biomarker, Janssen Research & Development, Shanghai 201210, China.
Wang X; Department of Biomarker, Janssen Research & Development, Shanghai 201210, China.
Cheng N; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Xia M; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Zhou T; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Liu Q; Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China.
Xu Y; Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China.
Yang J; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Gavine P; Department of Biology, Janssen Research & Development, Shanghai 201210, China.
Philippar U; Janssen Pharmaceutical Research & Development, Beerse 2340, Belgium.
Attar R; Janssen Pharmaceutical Research & Development, Spring House, Pennsylvania 19477, United States.
Edwards JP; Discovery Sciences, Janssen Research & Development, San Diego, California 92121, United States.
Venable JD; Discovery Sciences, Janssen Research & Development, San Diego, California 92121, United States.
Dai X; Discovery Sciences, Janssen (China) Research & Development, Shanghai 201210, P.R. China.; Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Aug 12; Vol. 64 (15), pp. 10878-10889. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Discovery*
Antineoplastic Agents/*pharmacology
Interleukin-1 Receptor-Associated Kinases/*antagonists & inhibitors
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Interleukin-1 Receptor-Associated Kinases/metabolism ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Lymphoma, Large B-Cell, Diffuse/pathology ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
3 H -Pyrazolo[4,3- f ]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo.
Autorzy :
Dayal N; Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.
Řezníčková E; Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic.
Hernandez DE; Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.
Peřina M; Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic.
Torregrosa-Allen S; Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.
Elzey BD; Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.; Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana 47907, United States.
Škerlová J; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic.; Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 14220, Czech Republic.
Ajani H; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic.
Djukic S; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic.
Vojáčková V; Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic.
Lepšík M; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic.
Řezáčová P; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic.; Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 14220, Czech Republic.
Kryštof V; Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic.
Jorda R; Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic.
Sintim HO; Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.; Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Aug 12; Vol. 64 (15), pp. 10981-10996. Date of Electronic Publication: 2021 Jul 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antineoplastic Agents/*pharmacology
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Structure-Activity Relationship ; Tumor Cells, Cultured ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Autorzy :
Wu L; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Zhang C; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
He C; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Qian D; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Lu L; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Sun Y; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Xu M; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Zhuo J; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Liu PCC; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Klabe R; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Wynn R; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Covington M; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Gallagher K; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Leffet L; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Bowman K; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Diamond S; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Koblish H; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Zhang Y; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Soloviev M; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Hollis G; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Burn TC; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Scherle P; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Yeleswaram S; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Huber R; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Yao W; Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Aug 12; Vol. 64 (15), pp. 10666-10679. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Discovery*
Morpholines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Pyrroles/*pharmacology
Receptor, Fibroblast Growth Factor, Type 1/*antagonists & inhibitors
Receptor, Fibroblast Growth Factor, Type 2/*antagonists & inhibitors
Receptor, Fibroblast Growth Factor, Type 3/*antagonists & inhibitors
Dose-Response Relationship, Drug ; Humans ; Molecular Structure ; Morpholines/chemical synthesis ; Morpholines/chemistry ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Pyrroles/chemical synthesis ; Pyrroles/chemistry ; Receptor, Fibroblast Growth Factor, Type 1/metabolism ; Receptor, Fibroblast Growth Factor, Type 2/metabolism ; Receptor, Fibroblast Growth Factor, Type 3/metabolism ; Structure-Activity Relationship ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes.
Autorzy :
Eduful BJ; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
O'Byrne SN; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Temme L; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Asquith CRM; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.; Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Liang Y; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Picado A; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Pilotte JR; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Hossain MA; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Wells CI; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Zuercher WJ; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Catta-Preta CMC; Centro de Química Medicinal (CQMED), Centro de Biologia Molecular e Engenharia Genética (CBMEG), Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo 13083-875, Brazil.; Structural Genomics Consortium, Departamento de Genética e Evolução, Instituto de Biologia, UNICAMP, Campinas, São Paulo 13083-886, Brazil.
Zonzini Ramos P; Centro de Química Medicinal (CQMED), Centro de Biologia Molecular e Engenharia Genética (CBMEG), Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo 13083-875, Brazil.; Structural Genomics Consortium, Departamento de Genética e Evolução, Instituto de Biologia, UNICAMP, Campinas, São Paulo 13083-886, Brazil.
Santiago AS; Centro de Química Medicinal (CQMED), Centro de Biologia Molecular e Engenharia Genética (CBMEG), Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo 13083-875, Brazil.; Structural Genomics Consortium, Departamento de Genética e Evolução, Instituto de Biologia, UNICAMP, Campinas, São Paulo 13083-886, Brazil.
Couñago RM; Centro de Química Medicinal (CQMED), Centro de Biologia Molecular e Engenharia Genética (CBMEG), Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo 13083-875, Brazil.; Structural Genomics Consortium, Departamento de Genética e Evolução, Instituto de Biologia, UNICAMP, Campinas, São Paulo 13083-886, Brazil.
Langendorf CG; St Vincent's Institute and Department of Medicine, The University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia.
Nay K; St Vincent's Institute and Department of Medicine, The University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia.; Mary MacKillop Institute for Health Research, Australian Catholic University, 215 Spring Street, Melbourne 3000, Australia.
Oakhill JS; St Vincent's Institute and Department of Medicine, The University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia.; Mary MacKillop Institute for Health Research, Australian Catholic University, 215 Spring Street, Melbourne 3000, Australia.
Pulliam TL; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.; Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas 77204, United States.; Department of Biology and Biochemistry, University of Houston, Houston, Texas 77204, United States.
Lin C; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas 77030, United States.
Awad D; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas 77030, United States.
Willson TM; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Frigo DE; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.; Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas 77204, United States.; Department of Biology and Biochemistry, University of Houston, Houston, Texas 77204, United States.; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.; The Methodist Hospital Research Institute, Houston, Texas 77030, United States.
Scott JW; St Vincent's Institute and Department of Medicine, The University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia.; Mary MacKillop Institute for Health Research, Australian Catholic University, 215 Spring Street, Melbourne 3000, Australia.; The Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville 3052, Australia.
Drewry DH; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.; UNC Lineberger Comprehensive Cancer Center, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Aug 12; Vol. 64 (15), pp. 10849-10877. Date of Electronic Publication: 2021 Jul 15.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Calcium/*pharmacology
Calcium-Calmodulin-Dependent Protein Kinase Kinase/*antagonists & inhibitors
Calmodulin/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Calcium/chemistry ; Calcium-Calmodulin-Dependent Protein Kinase Kinase/metabolism ; Calmodulin/chemistry ; Dose-Response Relationship, Drug ; Humans ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Autorzy :
Henderson SH; Sussex Drug Discovery Centre, University of Sussex, Brighton BN1 9RH, U.K.
Sorrell F; Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K.
Bennett J; Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, U.K.
Fedorov O; Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, U.K.
Hanley MT; Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.
Godoi PH; Structural Genomics Consortium, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil.
Ruela de Sousa R; Structural Genomics Consortium, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil.
Robinson S; Exscientia, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, U.K.
Ashall-Kelly A; Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.
Hopkins Navratilova I; Exscientia, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, U.K.; University of Dundee, Dow Street, Dundee DD1 5EH, U.K.
Walter DS; Evotec (UK) Ltd., 112-114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.
Elkins JM; Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K.; Structural Genomics Consortium, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil.
Ward SE; Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Aug 12; Vol. 64 (15), pp. 11709-11728. Date of Electronic Publication: 2021 Aug 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Discovery*
Protein Kinase Inhibitors/*pharmacology
Protein-Serine-Threonine Kinases/*antagonists & inhibitors
Protein-Tyrosine Kinases/*antagonists & inhibitors
Dose-Response Relationship, Drug ; HEK293 Cells ; Humans ; Ligands ; Molecular Structure ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/metabolism ; Protein-Serine-Threonine Kinases/metabolism ; Protein-Tyrosine Kinases/metabolism ; Solubility ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Autorzy :
Lücking U; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Kosemund D; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Böhnke N; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Lienau P; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Siemeister G; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Denner K; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Bohlmann R; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Briem H; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Terebesi I; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Bömer U; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Schäfer M; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Ince S; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Mumberg D; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Scholz A; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Izumi R; Vincerx Pharma, Inc., 260 Sheridan Avenue, Suite 400, Palo Alto, California 94306, United States.
Hwang S; Vincerx Pharma, Inc., 260 Sheridan Avenue, Suite 400, Palo Alto, California 94306, United States.
von Nussbaum F; Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Aug 12; Vol. 64 (15), pp. 11651-11674. Date of Electronic Publication: 2021 Jul 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Discovery*
Antineoplastic Agents/*pharmacology
Cyclin-Dependent Kinase 9/*antagonists & inhibitors
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cyclin-Dependent Kinase 9/metabolism ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Female ; Humans ; Injections, Intravenous ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Mice ; Mice, Nude ; Molecular Structure ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/chemistry ; Rats ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
Autorzy :
Xu D; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Sun D; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China; School of Life Science and Technology, Shanghai Tech University, 393 Middle Huaxia Road, Pudong New District, Shanghai, 201210, China.
Wang W; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Peng X; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Zhan Z; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Ji Y; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Shen Y; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Geng M; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China; School of Life Science and Technology, Shanghai Tech University, 393 Middle Huaxia Road, Pudong New District, Shanghai, 201210, China.
Ai J; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China; Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Xiangshan Branch Lane, Xihu District, Hangzhou, 330106, China. Electronic address: .
Duan W; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Aug 05; Vol. 220, pp. 113497. Date of Electronic Publication: 2021 Apr 25.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Discovery*
Antineoplastic Agents/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins/*antagonists & inhibitors
Pyrimidines/*pharmacology
Pyrroles/*pharmacology
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Male ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Proto-Oncogene Proteins/metabolism ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Pyrroles/chemical synthesis ; Pyrroles/chemistry ; Rats ; Rats, Sprague-Dawley ; Receptor Protein-Tyrosine Kinases/metabolism ; Structure-Activity Relationship ; Tumor Cells, Cultured
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies